Terminal heart failure: Who should be transplanted and who should have mechanical circulatory support?

Current Opinion in Organ Transplantation

Volumn 19, Issue 5, 2014, Pages 486-493

  Kirklin, James K ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cardiac surgery; Destination therapy; Mechanical circulatory support; Ventricular assist device

Indexed keywords

ASSISTED CIRCULATION; EMERGENCY HEALTH SERVICE; GRAFT SURVIVAL; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; LIFE SATISFACTION; MALIGNANT NEOPLASTIC DISEASE; MECHANICAL CIRCULATORY SUPPORT; PATIENT DECISION MAKING; PERIPARTUM CARDIOMYOPATHY; REVIEW; RISK FACTOR; TERMINAL DISEASE; VENTRICULAR ASSIST DEVICE; ADVERSE EFFECTS; HEART ASSIST DEVICE; HOSPITAL ADMISSION; PATIENT SELECTION; TREATMENT OUTCOME;

HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; PATIENT SELECTION; RISK FACTORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 84925710991     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000120     Document Type: Review

References (36)

1. Holman WL, Naftel DC, Eckert CE, et al. Durability of left ventricular assist devices: Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 2006 to 2011. J Thorac Cardiovasc Surg 2011;146:437-441.
2. Lund LH, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report - focus theme: age. J Heart Lung Transplant 2013;32:963-988. The thirtieth ISHLT Registry report provides important outcomes analyses from the world's largest heart transplant database.
3. Kirklin JK, Naftel DC, Kormos RL, et al. Fifth INTERMACS annual report: risk factor analysis from more than 6, 000 mechanical circulatory support patients. J Heart Lung Transplant 2013;32:141-156.
4. Kirklin JK, Naftel DC, Kormos RL, et al. Sixth INTERMACS annual report: a 10, 000 patient data base. J Heart Lung Transplant 2014;33:555-564. The sixth annual INTERMACS report provides detailed outcomes analyses from the world's largest database on mechanical circulatory support.
5. Strueber M, Larbalestier R, Jansz P, et al. Results of the post-market registry to evaluate the HeartWare left ventricular assist system (ReVOLVE). J Heart Lung Transplant 2014;33:486-491.
6. Kirklin JK, Naftel DC, Pagani FD, et al. Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation? J Thorac Cardiovasc Surg 2012;144:584-603.
7. Jorde UP, Kushwaha SS, Tatooles AJ, et al. Results of the destination therapy post-Food and Drug Administration Approval Study with a continuous flow left ventricular assist device. J Am College of Cardiol 2014;63:1751-1757.
8. Carmena MDGC, Bueno MG, Almenar L, et al. Primary graft failure after heart transplantation: characteristics in a contemporary cohort and performance of the RADIAL risk score. J Heart Lung Transplant 2013;32:1187-1195.
9. Kirklin JK, Naftel DC, Kormos RL, et al. Quantifying the effect of cardiorenal syndrome on mortality after left ventricular assist device implant. J Heart Lung Transplant 2013;32:1205-1213.
10. Brisco MA, Kimmel SE, Coca SG, et al. Prevalence and prognostic importance of changes in renal function after mechanical circulatory support. Circ Heart Fail 2014;7:68-75.
11. Dutt DP, Pinney SP. Clinical variability within the INTERMACS 1 profile: implications for treatment options. Curr Opin Cardiol 2014;29:244-249.
12. Dunlay SM, Park SJ, Joyce LD, et al. Frailty and outcomes after implantation of left ventricular assist device as destination therapy. J Heart Lung Transplant 2014;33:359-365.
13. Grady KL, Naftel DC, Stevenson L, et al. Overall quality of life improves to similar levels after mechanical circulatory support regardless of severity of heart failure before implantation. J Heart Lung Transplant 2014;33:412-421. This unique study documented not only major quality of life improvement following MCS therapy, but importantly the degree of improvement was not related to the severity of the preop condition.
14. Porepa LF, Starling RC. Destination therapy with left ventricular assist devices: for whom and when? Can J Cardiol 2014;30:296-303.
15. Zakliczynski M, Babinska A, Flak B, et al. Persistent mild lesions in coronary angiography predict poor long-term survival of heart transplant recipients. J Heart Lung Transplant 2014;33:618-623.
16. Higgins RS, Brown RN, Chang PP, et al. A multiinstitutional study of malignancies after heart transplantation and a comparison with the general United States population. J Heart Lung Transplant 2014;33:478-485.
17. Takeda K, Naka Y, Yang JA, et al. Outcome of unplanned right ventricular assist device support for severe right heart failure after implantable left ventricular assist device insertion. J Heart Lung Transplant 2014;33:141-148.
18. Stulak JM, Lee D, Haft JW, et al. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device. J Heart Lung Transplant 2014;33:60-64.
19. Goldstein DJ, Naftel D, Holman W, et al. Continuous-flow devices and percutaneous site infections: clinical outcomes. J Heart Lung Transplant 2012;31:117-126.
20. Starling RC, Moazami N, Silvestry SC, et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 2014;370:33-40. The high observed frequency of pump thrombosis during the most recent 2 years highlighted recent concerns about the susceptibility of continuous flow pumps to thrombosis.
21. Kirklin JK, Naftel DC, Kormos RL, et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant 2014;33:12-22. This analysis, which included most VAD centers in the USA, indicated a recent increase in the frequency of pump thrombosis, but of a smaller magnitude than reported by Starling et al. [20].
22. Cowger JA, Romano MA, Shah P, et al. Hemolysis: a harbinger of adverse outcome after left ventricular assist device implant. J Heart Lung Transplant 2014;33:35-43.
23. Ravichandran AK, Parker J, Novak E, et al. Hemolysis in left ventricular assist device: a retrospective analysis of outcomes. J Heart Lung Transplant 2014;33:44-50.
24. Baldwin JT, Mann DL. NHLBI's program for VAD therapy for moderately advanced heart failure: the REVIVE-IT pilot trial. J Card Fail 2010;16:855-858.
25. McIlvennan CK, Allen LA, Nowels C, et al. Decision making for destination therapy left ventricular assist devices: 'there was no choice' versus 'I thought about it an awful lot'. Circ Cardiovasc Qual Outcomes 2014;7:374-380.
26. Long EF, Swain GW, Mangi AA. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure. Circ Heart Fail 2014;8:470-478.
27. Teuteberg JJ, Stewart GC, Jessup M, et al. Implant strategies change over time and impact outcomes: insights from the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). JACC Heart Fail 2013;1:369-378. This analysis explores the frequency and outcomes of the 'bridge-to-decision' strategy of MCS support in the USA.
28. Kirklin JK, Naftel DC, Kormos RL, et al. The fourth INTERMACS annual report: 4, 000 implants and counting. J Heart Lung Transplant 2013;31:117-126.
29. Frazier OH, Cohn WE. Continuous-flow total heart replacement device implanted in a 55 year old man with end-stage heart failure and severe amyloidosis. Tex Heart Inst J 2012;39:542-546.
30. Smits JM, De Vries E, De Pauw M, et al. Is it time for a cardiac allocation score? First results from the Eurotransplant pilot study on a survival benefit-based heart allocation. J Heart Lung Transplant 2013;32:873-880. The Eurotransplant group presented a pilot study to refine donor prioritization, in part based on survival expectations after transplant.
31. Kato TS, Stevens GR, Jiang J, et al. Risk stratification of ambulatory patients with advanced heart failure undergoing evaluation for heart transplantation. J Heart Lung Transplant 2013;32:333-340.
32. Rasmusson K, Brunisholz K, Budge D, et al. Peripartum cardiomyopathy: post transplant outcomes from the United Network for Organ Sharing Database. J Heart Lung Transplant 2012;31:180-186.
33. Askar M, Hsich E, Reville P, et al. HLA and MICA allosensitization patterns among patients supported by ventricular assist devices. J Heart Lung Transplant 2013;32:1241-1248.
34. Oliveira GH, Dupont M, Naftel D, et al. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support. J Am Coll Cardiol 2014;63:240-248.
35. Argiriou M, Kolokotron SM, Sakellaridis T, et al. Right heart failure post left ventricular assist device implantation. J Thorac Dis 2014;6(Suppl 1):S52-S59.
36. Schima H, Zrunek P, Stoiber M, et al. Extended in vivo evaluation of a miniaturized axial flow pump with a novel inflow cannula for a minimal invasive implantation procedure. J Heart Lung Transplant 2014;33:422-428.